The aim of the present study is to investigate the correlation between EGFr expression and the reduction of TD during radiotherapy treatment and also to determine the dose per fraction to be taken into account when the OTT is reduced in accelerated radiotherapy of HNSCC. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.